Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003).

Yuan-Kai ShiJie CuiHui ZhouXiaohong ZhangLiqun ZouJunning CaoYuhuan GaoChuan JinXiaoling LiHui LiuZhigang PengLiping XieHuilai ZhangWeihua ZhangHongyu ZhangLiye ZhongFang ZhouGenny GuoWenduo He

Published in: Cancer immunology, immunotherapy : CII (2023)

Geptanolimab (GB226) demonstrated promising efficacy and a manageable safety profile in Chinese patients with r/r PMBCL.

Keyphrases

phase ii study
diffuse large b cell lymphoma
open label
locally advanced
acute lymphoblastic leukemia
lymph node
acute myeloid leukemia
multiple myeloma
hodgkin lymphoma
placebo controlled
radiation therapy
squamous cell carcinoma
study protocol